Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 2 3Phase NA 1Phase EARLY_PHASE1 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 97Prostatic Neoplasms 41Neoplasms 40Glioblastoma 26Melanoma 24Head and Neck Neoplasms 24Brain Neoplasms 24Ovarian Neoplasms 18Squamous Cell Carcinoma of Head and Neck 17Lung Neoplasms 17Carcinoma, Renal Cell 17Carcinoma, Hepatocellular 17Glioma 16Pancreatic Neoplasms 15Carcinoma, Non-Small-Cell Lung 15Leukemia, Myeloid, Acute 14Colorectal Neoplasms 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Urinary Bladder Neoplasms 10Lymphoma 10Uterine Cervical Neoplasms 9Polycystic Ovary Syndrome 9Lymphoma, Non-Hodgkin 9Fallopian Tube Neoplasms 9Endometrial Neoplasms 9Myelodysplastic Syndromes 8Multiple Myeloma 8Lymphoma, Mantle-Cell 8Lymphoma, Large B-Cell, Diffuse 8Skin Neoplasms 7

Interventions

Tetrahydrouridine 1Decitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Completed × Metastatic Pancreatic Adenocarcinoma × Clear all
NCT02847000 2019-01-09

p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Pancreatic Cancer

Case Comprehensive Cancer Center

Phase EARLY_PHASE1 Completed
13 enrolled
Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡